Sii Pneumosil Description

SII PNEUMOSIL (10-Valent) 0.5 ml - 1 dose: Each dose of 0.5 ml contains: Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A 2 mcg each; Saccharide for serotype 6B 4 mcg; Conjugated to CRM197 carrier protein 19 to 48 mcg; Aluminium (as Aluminium phosphate) 0.125 mg.
SII PNEUMOSIL (10-Valent) 2.5 ml - 5 dose: Each dose of 0.5 ml contains: Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A 2 mcg each; Saccharide for serotype 6B 4 mcg; Conjugated to CRM197 carrier protein 19 to 48 mcg; Aluminium (as Aluminium phosphate) 0.125 mg; Thiomersal: 0.005 %.
Dose: 0.5 ml by intramuscular injection.
SII PNEUMOSIL [Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) (10-valent)] is a sterile suspension of saccharides of the capsular antigens of Streptococcus pneumoniae serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F and 23F individually conjugated by using 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry (CDAP) to non-toxic diphtheria CRM197 protein. The polysaccharides are chemically activated and then covalently linked to the protein carrier CRM197 to form the glycoconjugate.
Individual conjugates are compounded and then polysorbate 20 and aluminium phosphate are added to formulate the vaccine. The potency of the vaccine is determined by the quantity of the saccharide antigens and the saccharide-to-protein ratios in the individual glycoconjugates. The vaccine meets the requirements of WHO, IP and BP when tested by the methods outlined in WHO TRS 977, IP and BP.